The big difference to our case is company A(Mylan) have never commercialised or paid any licensing fees to company B ( poh). Our grievance is more about stealing proprietary secrets.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025